April 26, 2023
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June… Read More
learn more
April 14, 2023
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced 27 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 in Orlando, Florida. The research described in the presentations includes real-world evidence supporting… Read More
learn more
April 3, 2023
Novocure to Report First Quarter 2023 Financial Results
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2023 on Thursday, May 4, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three months… Read More
learn more